DADA

DADA is the common abbreviation for diisopropylamine dichloroacetate, the diisopropylamine salt of dichloroacetic acid. Chemically it pairs the dichloroacetate anion, the active metabolic component, with a diisopropylamine counter-ion, and it is closely related to the more widely studied compound dichloroacetate (DCA), of which it can be considered a derivative ^[2]. The dichloroacetate portion is responsible for its defining pharmacology as an inhibitor of pyruvate dehydrogenase kinase.

The compound has a long clinical history in Japan, where it has been marketed for decades as an over-the-counter agent for chronic liver disease, a background that gives it an unusually established safety record for a molecule of continuing research interest ^[2][6]. Modern investigation was reinvigorated by work at Tokushima University identifying DADA specifically as an inhibitor of pyruvate dehydrogenase kinase 4 (PDK4), the isoform that rises in states of metabolic stress; in a mouse model of severe influenza, DADA restored the activity of the pyruvate dehydrogenase complex and improved survival ^[1].

Since then DADA has been examined across several fields. In oncology it has been studied for anti-tumor and radiosensitizing effects in breast, esophageal, and lung cancer models, generally exploiting the shift from glycolysis back to mitochondrial oxidation to raise reactive oxygen species and impair tumor growth ^[2][3][6]. In neurology it has been paired with melatonin to support remyelination in a model of multiple sclerosis ^[4], and reviews of influenza pathophysiology propose it as a way to correct the mitochondrial energy crisis that drives multiorgan failure ^[5]. DADA is not an approved drug in Western markets and is used there as a research chemical; it is typically encountered as a crystalline dichloroacetate salt.

REPORTED ADVERSE EFFECTS (Japanese Liverall label): headache; abdominal pain, dry mouth, loss of appetite; dry skin, gingival swelling. All listed as infrequent. In the 2005 NAFLD trial (PMID 15727691), 1 of 61 and 1 of 62 patients reported dry mouth (1.6%) over 8 weeks at 60 to 120 mg/d and no serious adverse reactions were recorded. GENOTOXICITY: DADA and its diisopropylamine component are both mutagenic in the Ames Salmonella assay (PMID 6752894); no carcinogenicity bioassay on DADA itself was found. Diisopropylamine is a vasodilator and a Russian clinical paper reports hypotensive activity of DADA in stage I to I-II hypertension (PMID 7047212, no abstract indexed), so a blood pressure effect is plausible but poorly characterised.

CLASS LEVEL CAUTION, LABELLED AS SUCH: chronic sodium dichloroacetate at 12.5 to 25 mg/kg/day causes dose dependent reversible peripheral neuropathy, shown in a randomised controlled MELAS trial stopped early for that reason (PMID 16476929, a DCA study, not a DADA study); DCA is cleared by GSTZ1, inhibits its own clearance, and GSTZ1 haplotype strongly changes exposure. By stoichiometry a 60 mg dose of DADA carries roughly 33 mg of dichloroacetate, about 0.5 mg/kg for a 70 kg adult, which is 25 to 50 times below those trial doses; that arithmetic is the reason label dose DADA is not expected to reproduce DCA neuropathy, but it is arithmetic and not a safety study.

REGULATORY: not a controlled or scheduled substance in any jurisdiction found. United States: no FDA approval; FDA Compliance Policy Guide 457.100 treats pangamic acid and pangamic acid products, which it describes as containing indiscriminate amounts of diisopropylammonium dichloroacetate, as unsafe for food and drug use and as unapproved new drugs, with an import alert dating to 1971. Japan: Japanese Accepted Name and long marketed, but Alfresa Pharma announced discontinuation of Liverall tablets 20 mg and Liverall powder 10% in January 2025 with an effective date of 1 November 2025, so the reference product is being withdrawn.

WADA: DADA and dichloroacetate are not named on the Prohibited List as far as could be checked, but this is UNVERIFIED because WADA's own list PDF and every national mirror tried blocked automated retrieval; S4.4 metabolic modulators is an open ended category, so a competing athlete should not treat "not named" as "permitted" without checking Global DRO. HORSE RACING: diisopropylamine is a prohibited substance in racing, DADA is metabolised to it, and detection methods target that metabolite (PMID 3215480; a 2023 metabolite identification paper, PMID 37459832, covers DIPA rather than DADA and is deliberately not listed as a DADA study above).

DADA (diisopropylamine dichloroacetate) is a salt combining diisopropylamine with dichloroacetate, and it has a long real-world history in Japan, where it has been available for decades as an over-the-counter agent for chronic liver disease, marketed under names such as Liverall. Interest in its metabolic mechanism grew as researchers recognized that its dichloroacetate moiety inhibits pyruvate dehydrogenase kinase, shifting cellular metabolism away from lactate and back toward mitochondrial oxidation. In more recent years it has been re-examined specifically as an inhibitor of the stress-induced isoform PDK4, with published work spanning severe infection, cancer, and metabolic disease. This combination of a long over-the-counter track record and renewed mechanistic research gives it an unusual dual profile among metabolic modulators.

DADA is viewed favorably in mitochondrial-health and metabolic circles for its clean, well-precedented mechanism: relieving PDK inhibition of pyruvate dehydrogenase to restore efficient oxidative metabolism. Researchers have found it attractive as a more potent relative of dichloroacetate, and recent studies report benefits ranging from improved survival in severe influenza models to enhanced anti-tumor immunity and radiosensitization of cancer cells.

Its decades-long availability in Japan lends a reassuring safety context that many experimental metabolic agents lack. At the same time, honesty requires noting that most of the exciting oncology and infection data come from cell and animal models rather than large human trials, and its established human use is specifically for liver support. It is an elegant metabolic switch with a strong mechanistic rationale and an expanding, still-maturing evidence base.